Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

1.225 -0.045 (-3.54%)
Streaming Delayed Price Updated: 3:09 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
From The Rosen Law Firm PA
Via GlobeNewswire
MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Expert Outlook: Macrogenics Through The Eyes Of 7 Analysts
Via Benzinga
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vicor and MacroGenics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
MacroGenics, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the MGNX Class Action
From Robbins LLP
Via Business Wire
NASDAQ:MGNX: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against MacroGenics, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. 
Via Benzinga
Topics Death
Exposures Death
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Match Group Layoffs 2024: What to Know About the Latest MTCH Job Cuts
Match Group layoffs are a hot topic on Wednesday as the dating website operator is preparing to reduce its headcount due to demand changes. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why is Macrogenics (MGNX) Stock Down 28% Today?
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial. 
Via InvestorPlace
Pinterest Issues Weak Revenue Forecast, Joins Groupon, O-I Glass And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning! 
Via InvestorPlace
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Shareholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against MacroGenics, Inc. (MGNX)
From Robbins LLP
Via GlobeNewswire
MACROGENICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MACROGENICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MacroGenics, Inc. - MGNX
From Kahn Swick & Foti, LLC
Via Business Wire
MacroGenics Provides Vobramitamab Duocarmazine Update
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
Confirming cash runway guidance into 2026 
From MacroGenics, Inc.
Via GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of MacroGenics, Inc. (MGNX) Investors
From Kirby McInerney LLP
Via Business Wire
MGNX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces That MacroGenics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
MACROGENICS, INC. (NASDAQ: MGNX) INVESTOR ALERT: Investors With Large Losses in MacroGenics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
MacroGenics to Participate in Upcoming Investor Conference
From MacroGenics, Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.